Category Archives: Bad for Schering Boceprivir Good for Vertex Telaprevir

One Trend-Buster: A High-Flying Pharma Sector Stock — Vertex — on Hep C Candidate-Trials. . . .

. . .Meanwhile [as Merck prepares to let us all know how much the woes of Vytorin/Zetia will affect it (and Schering) in the future], Needham Securities just this morning upgraded Vertex to a “Buy” — from “Hold” — and Vertex is up another almost 5 percent today, trading at $34.50, as I write this. That bumps the post-public secondary offering gain (priced at $25.50) to almost 36 percent in eight days. Wow.

Sweet! — add about 20 percent — to the above chart, for Vertex. [The background — on this action — is here.]